Argenx NV’s American depositary receipts reached a historic intraday peak of $1,059.86 on Thursday, capping a 49.91% gain over the prior 12 months and pushing its market capitalization to $66 billion.
The advance reflects accelerating revenue growth of roughly 70% over the trailing 12-month period, driven by robust demand for the company’s flagship rare-disease therapy Vyvgart. Analysts also cited positive data from the Phase 3 ALKIVIA study in myositis, which met its primary endpoint, as a key catalyst for investor sentiment.
UBS upgraded its rating to Buy from Neutral and raised its price target to $1,400, the most bullish outlook among covering firms. Deutsche Bank trimmed its stance to Hold from Buy but lifted its target to €925, while RBC Capital maintained an Outperform rating with a new target of $1,100. TD Cowen also kept its Buy rating and increased its target to $1,353, citing higher revenue expectations for Vyvgart through fiscal 2027.
Citizens retained a Market Outperform rating with a $1,200 target. The stock’s record close follows a period of sustained appreciation, coinciding with the drug’s expanding indications and commercial traction in underserved patient populations.
